Key Development
According to the latest macroeconomic data released by the General Statistics Office (Ministry of Finance), the Consumer Price Index (CPI) for the Medicines and Medical Services category rose 1.24% year-on-year (YoY) in July 2026. For the first seven months of 2026, the healthcare index recorded an average increase of 1.06% compared to the corresponding period in 2025.
The inflationary pressure across the healthcare basket is primarily attributed to rising costs associated with imported active pharmaceutical ingredients (APIs), manufacturing operations, and global freight/distribution logistics.
Granular Breakdown of Healthcare Price Index Movements:
-
Comparison with December 2025 (Year-to-Date): The medicines and healthcare services index expanded by 1.05%. Specific sub-indices include:
-
Pharmaceutical Formulations: Increased by 1.71%.
-
Medical Equipment & Instruments: Increased by 1.70%.
-
Clinical Healthcare Services: Increased by 0.72%.
-
-
Month-on-Month (MoM) Movements (July vs. June 2026): Healthcare CPI registered a modest increase of 0.07% (representing one of eight consumer baskets recording price increases). Sub-therapeutic movements included:
-
NSAIDs, Antipyretics, Gout, and Musculoskeletal Therapeutics: Increased by 0.28%.
-
Respiratory System Agents: Increased by 0.21%.
-
Anti-Infective & Anti-Parasitic Therapies: Increased by 0.18%.
-
Antihistamines & Anti-Allergy Formulations: Increased by 0.16%.
-
Outpatient Clinical Examination Services: Increased by 0.05%.
-
-
Statutory Pricing Control Instruments: To curb healthcare inflation and protect patient access, the Ministry of Health (MOH) enforces a statutory retail pharmacy mark-up cap (thặng số bán lẻ) ranging between 2.5% and 15% within public hospital pharmacies; complemented by mandatory pre-market wholesale and retail price declaration requirements for domestic manufacturers and pharmaceutical importers.
Why It Matters
-
Structural Exposure to Upstream API Imports: Vietnam’s domestic finished pharmaceutical manufacturing sector relies on imports for roughly 80–90% of its active pharmaceutical ingredients (principally sourced from India and China). Currency fluctuations (USD/VND) and stricter international environmental standards have elevated input procurement costs, which translate into price adjustments across frontline essential therapeutic classes.
-
Out-of-Pocket Expenditure & Social Health Insurance Solvency: Simultaneous price increases in pharmaceuticals (+1.71%) and medical consumables (+1.70%) elevate out-of-pocket (OOP) co-payments for retail consumers while exerting budgetary pressure on the national Vietnam Health Insurance (VHI) reimbursement fund.
-
Efficacy of Statutory Hospital Retail Caps: Enforcing statutory mark-up limits (capped at 2.5% for high-cost products) prevents hospital pharmacies from inflating margins, maintaining healthcare CPI growth (1.24%) significantly below headline national inflation (4.45%).
Healthcare Insight Analysis
From the perspective of Healthcare Insight, the July 2026 healthcare macroeconomic indicators illustrate Cost-Push Healthcare Inflation & Statutory Margin Caps.
The healthcare marketplace operates under three primary economic forces:
-
Seasonal Demand Surges Across Respiratory and Anti-Inflammatory Categories: The higher price velocity recorded in NSAIDs (+0.28%) and respiratory products (+0.21%) reflects seasonal disease transmission patterns and increased retail over-the-counter (OTC) purchasing.
-
Mitigating Speculative Pricing via Tiered Mark-Up Caps: The statutory inverse mark-up formula—where higher-priced innovator biologics and specialty drugs are subject to smaller percentage mark-up limits (down to 2.5%)—effectively constrains retailer margins on expensive chronic therapies.
-
Gross Margin Compression for Domestic Drug Manufacturers: Domestic pharmaceutical manufacturers (such as DHG Pharma, Traphaco, Imexpharm, and Vidipha) face rising API costs and EU-GMP compliance expenditures, while public hospital tender ceilings limit price increases, driving enterprise focus toward manufacturing efficiency.
Market Implications
-
Intensified Regulatory Audits on Declared Drug Wholesale Prices: The Drug Administration of Vietnam (DAV) and pricing oversight agencies will increase compliance audits on declared import wholesale prices to prevent transfer pricing practices.
-
Scale Advantages for Modern Pharmacy Chains (Long Chau, Pharmacity, An Khang): Large retail pharmacy chains will leverage high-volume procurement contracts to secure preferential pricing from manufacturers, capturing market share from fragmented traditional pharmacies.
-
Incentivizing Domestic API and Excipient Manufacturing: Highlights the strategic rationale for state policies that incentivize domestic chemical synthesis and high-tech excipient production to decouple the domestic supply chain from international supply shocks.
Macroeconomic Profile Matrix: Vietnam Healthcare CPI (July 2026)
| Parameter / Sub-Index | CPI Movement Rate | Primary Drivers & Governance Mechanics |
| Healthcare CPI (YoY vs. July 2025) | +1.24% Expansion (Headline CPI: +4.45%) | Driven by imported raw material, manufacturing & logistics costs. |
| 7-Month Average (Jan–Jul 2026) | +1.06% YoY Average | Demonstrates relative price stability compared to headline CPI. |
| Pharmaceuticals Sub-Index | +1.71% vs. Dec 2025 | Reflects rising active pharmaceutical ingredient (API) procurement costs. |
| Medical Devices & Consumables | +1.70% vs. Dec 2025 | Influenced by imported medical equipment components and supply chains. |
| Clinical Services Sub-Index | +0.72% vs. Dec 2025 | Marginal upward adjustment in outpatient examination tariffs (+0.05%). |
| Leading Monthly Gainers (MoM) | NSAIDs/Musculoskeletal (+0.28%), Respiratory (+0.21%) | Elevated therapeutic consumption and seasonal OTC demand. |
| Statutory Price Governance | 2.5% – 15% Retail Hospital Mark-Up Cap | Enforces price ceiling transparency for inpatient/outpatient hospital pharmacies. |
Source: https://thanhnien.vn/gia-thuoc-va-dich-vu-y-te-deu-co-xu-huong-tang-1852608241226559.htm